November 22, 2025 - 05:26

U.S. stocks experienced a significant uptick on Friday, with the Dow and S&P 500 each climbing approximately 1%, while the Nasdaq rose just shy of 1%. However, despite this daily rally, all three major indexes recorded losses for the week, primarily driven by apprehensions surrounding elevated technology valuations.
The week was notably impacted by Nvidia, whose shares initially surged following a robust earnings report. However, a subsequent selloff ensued, contributing to broader market declines. Anna Rathbun, founder and CEO of Grenadilla Advisory, commented on the situation, suggesting that the market reaction to Nvidia was exaggerated. She noted that while Nvidia's performance sparked concern, it shouldn't have triggered a sell-off across the board.
Meanwhile, Nvidia's stock saw a brief increase after reports indicated that the Trump administration might allow sales of its H200 AI chips to China, though it ultimately closed down 1%. In contrast, Eli Lilly's shares rose by 1.5% as the company became the first drugmaker to reach a $1 trillion market capitalization. Additionally, Gap's stock surged over 8% after surpassing Wall Street expectations for third-quarter sales and profits, buoyed by strong demand for its Old Navy and Banana Republic brands.
November 11, 2026 - 03:35
Resideo Reports Third Quarter 2026 Financial Performance and Outlook UpdateResideo Technologies, Inc. has shared its financial results for the third quarter of 2026, which concluded on October 3. The company, known for its innovative control and sensing solutions in the...
November 10, 2026 - 13:34
Hong Kong's Financial Transformation: China Aims for Global InfluenceA recent report explores how Beijing is reshaping Hong Kong into a key player in the global financial landscape. The analysis, conducted by ASPI`s Center for China Analysis and Enodo Economics,...
November 10, 2026 - 09:52
BitGo Holdings Reports Significant Revenue Decline in Q3BitGo Holdings, known by the ticker BTGO, has revealed a troubling 50.9% drop in year-over-year revenue for the third quarter. The decline is largely attributed to a slowdown in digital asset...
November 9, 2026 - 21:06
New Drug Application Submitted for Azetukalner in Focal SeizuresIn September 2026, a New Drug Application for azetukalner, a treatment for focal seizures, was submitted to the U.S. Food and Drug Administration. This marks a significant step forward in expanding...